Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
4.39 ^USD	-3.30%		-6.30%	+68.20%

May. 07	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
May. 01	Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024	May. 01	BU
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024	Apr. 24	BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	Apr. 11	BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	Apr. 10	BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 25	AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024	Mar. 14	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	Mar. 11	PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	Mar. 05	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	Mar. 03	PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Feb. 26	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023	Feb. 20	BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	Feb. 15	AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024	Feb. 14	BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	Feb. 08	AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	Feb. 08	AQ
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 07	BU
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	BU
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Press Releases

Filters